NASDAQ:ALLO Allogene Therapeutics (ALLO) Stock Price, News & Analysis $1.69 0.00 (0.00%) Closing price 09/21/2026 04:00 PM EasternExtended Trading$1.70 +0.01 (+0.83%) As of 08:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Allogene Therapeutics Stock (NASDAQ:ALLO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Allogene Therapeutics alerts:Sign Up Key Stats Today's Range$1.65▼$1.7250-Day Range$1.66▼$2.2352-Week Range$1.04▼$4.46Volume5.99 million shsAverage Volume5.23 million shsMarket Capitalization$583.88 millionP/E RatioN/ADividend YieldN/APrice Target$8.30Consensus RatingModerate Buy Company Overview Allogene Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing “off-the-shelf” allogeneic CAR T-cell therapies for the treatment of cancer. Unlike autologous CAR T treatments, which are manufactured from an individual patient’s own cells, Allogene’s therapies are designed to use T cells collected from healthy donors, potentially supporting more standardized manufacturing and broader patient access. The company’s investigational pipeline includes cemacabtagene ansegedleucel (cema-cel, formerly ALLO-501A), an anti-CD19 CAR T-cell therapy being evaluated in B-cell malignancies, and ALLO-715, an anti-BCMA CAR T-cell therapy being studied for multiple myeloma. Allogene is also developing additional cell therapies targeting blood cancers and solid tumors. These products remain investigational and have not been approved for commercial use. Allogene was founded in 2018 by former leaders of Kite Pharma and is headquartered in South San Francisco, California. The company’s programs are evaluated through clinical development activities and collaborations involving research and medical institutions in the United States and other regions. David Chang, M.D., Ph.D., is the company’s co-founder, president and chief executive officer.AI Generated. May Contain Errors. Read More Allogene Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreALLO MarketRank™: Allogene Therapeutics scored higher than 42% of companies evaluated by MarketBeat, and ranked 607th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingAllogene Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 1 strong buy rating, 8 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialAllogene Therapeutics has a consensus price target of $8.30, representing about 391.1% upside from its current price of $1.69.Amount of Analyst CoverageAllogene Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Allogene Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Allogene Therapeutics are expected to decrease in the coming year, from ($0.59) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allogene Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allogene Therapeutics is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllogene Therapeutics has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Allogene Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.71% of the float of Allogene Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllogene Therapeutics has a short interest ratio ("days to cover") of 12.15, which indicates bearish sentiment.Change versus previous monthShort interest in Allogene Therapeutics has recently increased by 0.29%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAllogene Therapeutics does not currently pay a dividend.Dividend GrowthAllogene Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentAllogene Therapeutics has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Healthcare companies.Search Interest16 people have searched for ALLO on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Allogene Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Allogene Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $62,958.00 in company stock.Percentage Held by Insiders13.20% of the stock of Allogene Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.63% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Allogene Therapeutics' insider trading history. Receive ALLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALLO Stock News HeadlinesAllogene CEO Zach Roberts is pushing to make CAR T-cell therapy more accessible: 'That's what gets me out of bed'September 10, 2026 | msn.comAllogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 9, 2026 | seekingalpha.comA councilman backed AI — then 13 bullets hit his front doorThirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Across the country, protests, lawsuits, and moratoria are targeting AI infrastructure projects. Whitney Tilson, former hedge fund manager and editor of Stansberry's Investment Advisory, says November 4 could bring this conflict to a head, with major implications for investors' portfolios.September 22 at 1:00 AM | Stansberry Research (Ad)Allogene: If MRD Holds, This Becomes A Completely Different CompanySeptember 7, 2026 | seekingalpha.comAllogene Chief Financial Officer Geoffrey Parker RetiringSeptember 4, 2026 | marketwatch.comAllogene's Executive VP & CFO Geoffrey Parker To RetireSeptember 2, 2026 | rttnews.comAllogene Therapeutics CFO Geoffrey Parker to RetireSeptember 2, 2026 | marketscreener.comMAllogene Therapeutics (NASDAQ:ALLO) SVP Sells 29,697 Shares of StockAugust 26, 2026 | insidertrades.comSee More Headlines ALLO Stock Analysis - Frequently Asked Questions How have ALLO shares performed this year? Allogene Therapeutics' stock was trading at $1.37 at the start of the year. Since then, ALLO stock has increased by 23.4% and is now trading at $1.69. How were Allogene Therapeutics' earnings last quarter? Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.04. The firm earned $4.64 million during the quarter, compared to the consensus estimate of $0 million. Read the conference call transcript. When did Allogene Therapeutics IPO? Allogene Therapeutics (ALLO) raised $306 million in an initial public offering on Thursday, October 11th 2018. The company issued 18,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies served as the underwriters for the IPO. Who are Allogene Therapeutics' major shareholders? Allogene Therapeutics' top institutional investors include BlackRock Inc. (8.73%), Frazier Life Sciences Management L.P. (6.50%), Primecap Management Co. CA (3.80%) and Walleye Capital LLC (0.95%). Insiders that own company stock include David D Chang, Arie Belldegrun, Geoffrey M Parker, Zachary Roberts, Earl Martin Douglas, Franz B Humer, Timothy L Moore, Benjamin Machinas Beneski and Annie Yoshiyama. View institutional ownership trends. How do I buy shares of Allogene Therapeutics? Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Allogene Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allogene Therapeutics investors own include Waste Connections (WCN), American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/12/2026Today9/22/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 13 days, ALLO's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ALLO CIK1737287 Webwww.allogene.com Phone(650) 457-2700FaxN/AEmployees152Year Founded2018Price Target and Rating Average Price Target for Allogene Therapeutics$8.30 High Price Target$14.00 Low Price Target$3.85 Potential Upside/Downside+391.1%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$190.89 million Net MarginsN/A Pretax Margin-3,710.63% Return on Equity-50.04% Return on Assets-36.74% Debt Debt-to-Equity RatioN/A Current Ratio10.72 Quick Ratio10.72 Sales & Book Value Annual Sales$20 thousand Price / Sales29,193.91 Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book1.30Miscellaneous Outstanding Shares345,490,000Free Float299,886,000Market Cap$583.88 million OptionableOptionable Beta0.47 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ALLO) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our PartnersThe AI Infrastructure Rush Is ON — Watch VDTAVertical Data Inc. (OTCQB: VDTA) is targeting the infrastructure layer beneath the AI boom, from GPU hardware ...Trading Wire | SponsoredChina's dominance in rare earth processing sparks new defense rulesOn January 1, 2027, new Pentagon rules tighten sourcing restrictions on critical minerals tied to foreign adve...The Tomorrow Investor | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredArizona Gold Explorer Nears First-Ever Resource EstimateA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...Wall Street Logic | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLO Stock Alerts